Four new ZonMw awards highlight the strength of the academic drug discovery ecosystem on the VU campus, where medicinal chemists of the Amsterdam Institute of Molecular and Life Sciences (AIMMS) are increasingly joining forces with colleagues from the VU’s Center for Neurogenomics and Cognitive Research (CNCR) and Amsterdam UMC neuroscientists to accelerate the development of new Alzheimer’s therapies.

A key factor underlying this success is the strong cross-disciplinary collaboration across the VU Amsterdam campus. Although the projects target different aspects of Alzheimer’s disease, the principal investigators are closely connected, regularly exchange expertise, and actively support each other’s projects. This collaborative network fosters synergy between complementary approaches, accelerating scientific progress while strengthening the translation of discoveries into meaningful treatments for patients.

Within this collaborative framework, the funded projects address several complementary therapeutic strategies.
The awarded projects include:

Ruud Wijdeven (Amsterdam UMC,  Candidate Center) and Iwan de Esch (VU AIMMS, Chemistry & Pharmaceutical Sciences) focus on compounds that may block the cellular uptake of toxic APOE4, a major genetic risk factor for Alzheimer’s disease.
Iwan de Esch (VU AIMMS) and Wiep Scheper (VU CNCR and Amsterdam UMC, Human Genetics) are working on dual inhibition of PDE4 and PDE7, with the aim of combining anti-inflammatory and cognition-supporting effects in a single therapeutic strategy.
Rik van der Kant (VU CNCR and Alzheimer Center Amsterdam, Amsterdam UMC) is investigating whether existing drugs can reduce fibronectin levels and help protect the blood–brain barrier in APOE4 carriers.
Rob Leurs (VU AIMMS, Chemistry & Pharmaceutical Sciences) and Elga de Vries (Amsterdam UMC, Molecular Cell Biology & Immunology) are studying ACKR3 as a target to reduce harmful immune cell entry into the brain and limit neuroinflammation.

What makes this achievement particularly is the strong, cross-discipline collaboration between researchers across disciplines and institutions on the VU Amsterdam campus.  Despite working on different aspects of Alzheimer’s disease, the principal investigators are closely connected, regularly exchange expertise, and actively support each other’s projects. This integrated approach not only accelerates scientific progress but also increases the likelihood that promising discoveries will translate into meaningful treatments for patients.

Leave a Reply